Minerva Surgical, Inc IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Minerva Surgical, Inc | UTRS - NASDAQ |
$15.00-$17.00 | $12.00 | $9.66 | 6.25 million | 10/22/2021 |
| J.P. Morgan, Piper Sandler, UBS Investment Bank, SVB Leerink | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Filed 2021-09-27 Terms Added 2021-10-15 | ||||||
Minerva Surgical, Inc Quote & Chart - Click for current quote - UTRS
IPO Boutique aggregates information on public companies and private companies, such as "UTRS" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Minerva Surgical, Inc (adapted from Minerva Surgical, Inc prospectus):
They are a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a commercial-stage medical technology company focused on developing, manufacturing, and commercializing minimally invasive solutions to meet the distinct uterine healthcare needs of women.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "UTRS" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.